Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Similar long-term survival of consecutive in-hospital and out-of-hospital cardiac arrest patients treated with targeted temperature management.

Engsig M, Søholm H, Folke F, Gadegaard PJ, Wiis JT, Molin R, Mohr T, Engsig FN.

Clin Epidemiol. 2016 Nov 9;8:761-768. eCollection 2016.

2.

Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial.

Jensen JS, Itenov TS, Thormar KM, Hein L, Mohr TT, Andersen MH, Løken J, Tousi H, Lundgren B, Boesen HC, Johansen ME, Ostrowski SR, Johansson PI, Grarup J, Vestbo J, Lundgren JD; Procalcitonin And Survival Study (PASS) Group..

Ann Intensive Care. 2016 Dec;6(1):114. Epub 2016 Nov 21.

3.

Prognostic Implications of Level-of-Care at Tertiary Heart Centers Compared With Other Hospitals After Resuscitation From Out-of-Hospital Cardiac Arrest.

Søholm H, Kjaergaard J, Bro-Jeppesen J, Hartvig-Thomsen J, Lippert F, Køber L, Nielsen N, Engsig M, Steensen M, Wanscher M, Karlsen FM, Hassager C.

Circ Cardiovasc Qual Outcomes. 2015 May;8(3):268-76. doi: 10.1161/CIRCOUTCOMES.115.001767. Epub 2015 May 5.

4.

Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime.

Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr T, Andersen MH, Løken J, Tousi H, Søe-Jensen P, Lauritsen AØ, Strange D, Petersen JA, Thormar K, Larsen KM, Drenck NE, Helweg-Larsen J, Johansen ME, Reinholdt K, Møller JK, Olesen B, Arendrup MC, Østergaard C, Cozzi-Lepri A, Grarup J, Lundgren JD; Procalcitonin and Survival Study Group..

Crit Care Med. 2015 Mar;43(3):594-602. doi: 10.1097/CCM.0000000000000746.

PMID:
25493970
5.

Serum and plasma neutrophil gelatinase associated lipocalin (NGAL) levels are not equivalent in patients admitted to intensive care.

Itenov TS, Bangert K, Christensen PH, Jensen JU, Bestle MH; Procalcitonin and Survival Study (PASS)-study group..

J Clin Lab Anal. 2014 Mar;28(2):163-7. doi: 10.1002/jcla.21662. Epub 2014 Jan 6.

PMID:
24395189
6.

Determination of flomoxef in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.

Kravtsova OY, Paramonov SA, Vasilevich NI, Kazyulkin DN, Vlasova E, Engsig M.

Biomed Chromatogr. 2013 Dec;27(12):1609-14. doi: 10.1002/bmc.2968. Epub 2013 Jun 18.

PMID:
23780743
7.

Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial.

Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Løken J, Steensen M, Fox Z, Tousi H, Søe-Jensen P, Lauritsen AØ, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjær J, Grarup J, Lundgren JD; Procalcitonin And Survival Study (PASS) Group..

Crit Care Med. 2011 Sep;39(9):2048-58. doi: 10.1097/CCM.0b013e31821e8791.

PMID:
21572328
8.

The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation.

Schaller S, Henriksen K, Sveigaard C, Heegaard AM, Hélix N, Stahlhut M, Ovejero MC, Johansen JV, Solberg H, Andersen TL, Hougaard D, Berryman M, Shiødt CB, Sørensen BH, Lichtenberg J, Christophersen P, Foged NT, Delaissé JM, Engsig MT, Karsdal MA.

J Bone Miner Res. 2004 Jul;19(7):1144-53. Epub 2004 Mar 1. Erratum in: J Bone Miner Res. 2004 Aug;19(8):1378.

9.

Measurement of tumor load and distribution in a model of cancer-induced osteolysis: a necessary precaution when testing novel anti-resorptive therapies.

Amhlaoibh RN, Hoegh-Andersen P, Brünner N, Sørensen A, Winding B, Holst-Hansen C, Karsdal MA, Engsig MT, Delaissé JM, Heegaard AM.

Clin Exp Metastasis. 2004;21(1):65-74.

PMID:
15065604
10.

RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism.

Henriksen K, Karsdal M, Delaisse JM, Engsig MT.

J Biol Chem. 2003 Dec 5;278(49):48745-53. Epub 2003 Sep 23.

11.
12.

Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities.

Delaissé JM, Andersen TL, Engsig MT, Henriksen K, Troen T, Blavier L.

Microsc Res Tech. 2003 Aug 15;61(6):504-13. Review.

PMID:
12879418
13.

Investigation of bone disease using isomerized and racemized fragments of type I collagen.

Cloos PA, Fledelius C, Christgau S, Christiansen C, Engsig M, Delmas P, Body JJ, Garnero P.

Calcif Tissue Int. 2003 Jan;72(1):8-17. Epub 2002 Oct 21.

PMID:
12384813
14.

Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis.

Karsdal MA, Larsen L, Engsig MT, Lou H, Ferreras M, Lochter A, Delaissé JM, Foged NT.

J Biol Chem. 2002 Nov 15;277(46):44061-7. Epub 2002 Sep 10.

15.

Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones.

Engsig MT, Chen QJ, Vu TH, Pedersen AC, Therkidsen B, Lund LR, Henriksen K, Lenhard T, Foged NT, Werb Z, Delaissé JM.

J Cell Biol. 2000 Nov 13;151(4):879-89. Erratum in: J Cell Biol 2001 Jan 22;152(2):following 417.

16.

Proteinases in bone resorption: obvious and less obvious roles.

Delaissé JM, Engsig MT, Everts V, del Carmen Ovejero M, Ferreras M, Lund L, Vu TH, Werb Z, Winding B, Lochter A, Karsdal MA, Troen T, Kirkegaard T, Lenhard T, Heegaard AM, Neff L, Baron R, Foged NT.

Clin Chim Acta. 2000 Feb 15;291(2):223-34. Review.

PMID:
10675725

Supplemental Content

Loading ...
Support Center